ES2549860T3 - Diagnóstico y pronóstico de estados patológicos relacionados con la dipepitidil peptidasa - Google Patents
Diagnóstico y pronóstico de estados patológicos relacionados con la dipepitidil peptidasa Download PDFInfo
- Publication number
- ES2549860T3 ES2549860T3 ES07753293.5T ES07753293T ES2549860T3 ES 2549860 T3 ES2549860 T3 ES 2549860T3 ES 07753293 T ES07753293 T ES 07753293T ES 2549860 T3 ES2549860 T3 ES 2549860T3
- Authority
- ES
- Spain
- Prior art keywords
- dpp
- activity
- measured
- portions
- parameter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001575 pathological effect Effects 0.000 title description 9
- 238000003745 diagnosis Methods 0.000 title description 4
- 238000004393 prognosis Methods 0.000 title description 4
- 102000035195 Peptidases Human genes 0.000 title 1
- 108091005804 Peptidases Proteins 0.000 title 1
- 235000019833 protease Nutrition 0.000 title 1
- 230000000694 effects Effects 0.000 abstract description 47
- 102000001708 Protein Isoforms Human genes 0.000 abstract description 44
- 108010029485 Protein Isoforms Proteins 0.000 abstract description 44
- 201000010099 disease Diseases 0.000 abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 238000000034 method Methods 0.000 abstract description 10
- 230000004481 post-translational protein modification Effects 0.000 abstract description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 7
- 239000013610 patient sample Substances 0.000 abstract description 4
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 abstract 2
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 abstract 2
- 208000016097 disease of metabolism Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 45
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 45
- 238000005259 measurement Methods 0.000 description 24
- 206010012601 diabetes mellitus Diseases 0.000 description 19
- 239000000523 sample Substances 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 238000001155 isoelectric focusing Methods 0.000 description 9
- 238000001997 free-flow electrophoresis Methods 0.000 description 6
- 102000004856 Lectins Human genes 0.000 description 5
- 108090001090 Lectins Proteins 0.000 description 5
- 241000282898 Sus scrofa Species 0.000 description 5
- 239000002523 lectin Substances 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 102000045598 human DPP4 Human genes 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- UTDVHCQTKWTQEA-UHFFFAOYSA-N 1-(2-aminoacetyl)-n-(4-methyl-2-oxochromen-7-yl)pyrrolidine-2-carboxamide Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1NC(=O)C1CCCN1C(=O)CN UTDVHCQTKWTQEA-UHFFFAOYSA-N 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78192406P | 2006-03-13 | 2006-03-13 | |
| US781924P | 2006-03-13 | ||
| US80439706P | 2006-06-09 | 2006-06-09 | |
| US804397P | 2006-06-09 | ||
| US89276707P | 2007-03-02 | 2007-03-02 | |
| US892767P | 2007-03-02 | ||
| PCT/US2007/006653 WO2007106595A1 (en) | 2006-03-13 | 2007-03-13 | Diagnosis and prognosis of dipeptidyl peptidase-associated disease states |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2549860T3 true ES2549860T3 (es) | 2015-11-02 |
Family
ID=38265130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07753293.5T Active ES2549860T3 (es) | 2006-03-13 | 2007-03-13 | Diagnóstico y pronóstico de estados patológicos relacionados con la dipepitidil peptidasa |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8652789B2 (https=) |
| EP (1) | EP1994415B9 (https=) |
| JP (1) | JP5410955B2 (https=) |
| KR (1) | KR101376471B1 (https=) |
| CN (1) | CN101460851B (https=) |
| AU (1) | AU2007225054B2 (https=) |
| BR (1) | BRPI0708900A2 (https=) |
| CA (1) | CA2645302C (https=) |
| ES (1) | ES2549860T3 (https=) |
| MX (1) | MX2008011665A (https=) |
| WO (1) | WO2007106595A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2527649T3 (es) * | 2007-12-10 | 2015-01-28 | F. Hoffmann-La Roche Ag | Panel de marcadores para el cáncer colorrectal |
| ES2533428T3 (es) * | 2009-05-04 | 2015-04-10 | F. Hoffmann-La Roche Ag | Uso de DPPIV/Seprasa como un marcador para el cáncer |
| JP6065172B2 (ja) * | 2010-10-22 | 2017-01-25 | 国立大学法人名古屋大学 | 微小血管障害又はその関連疾患のバイオマーカー |
| US20140273008A1 (en) * | 2013-03-15 | 2014-09-18 | Molecular Bioproducts, Inc. | Methods to assess enzyme activity using mass spectrometric immunoassay |
| EP3314004A1 (en) * | 2015-06-26 | 2018-05-02 | DuPont Nutrition Biosciences ApS | Aminopeptidases for protein hydrolyzates |
| AU2017252212B2 (en) * | 2016-04-21 | 2023-09-07 | 4TEEN4 Pharmaceuticals GmbH | Methods for determining DPP3 and therapeutic methods |
| CN110426518A (zh) * | 2019-07-19 | 2019-11-08 | 宁波熙宁检测技术有限公司 | 一种定量检测人类血浆中dpp-4酶活性的方法 |
| EP4308937B1 (en) * | 2021-03-16 | 2026-02-04 | Astrazeneca AB | System and method for online detection of a post-translational modification of a polypeptide |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4900662A (en) | 1987-07-21 | 1990-02-13 | International Immunoassay Laboratories, Inc. | CK-MM myocardial infarction immunoassay |
| US5382515A (en) | 1987-07-21 | 1995-01-17 | International Immunoassay Laboratories, Inc. | Creative kinase-MB immunoassay for myocardial infarction and reagents |
| US5382522A (en) | 1987-07-21 | 1995-01-17 | International Immunoassay Laboratories, Inc. | Immunoassay for creatine kinase-MB and creatine kinase-BB isoforms and reagents |
| EP1631680A2 (en) * | 2003-05-21 | 2006-03-08 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4) |
| US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
-
2007
- 2007-03-13 CN CN200780016051.1A patent/CN101460851B/zh active Active
- 2007-03-13 WO PCT/US2007/006653 patent/WO2007106595A1/en not_active Ceased
- 2007-03-13 AU AU2007225054A patent/AU2007225054B2/en active Active
- 2007-03-13 JP JP2009500509A patent/JP5410955B2/ja active Active
- 2007-03-13 KR KR1020087024813A patent/KR101376471B1/ko active Active
- 2007-03-13 EP EP07753293.5A patent/EP1994415B9/en not_active Not-in-force
- 2007-03-13 ES ES07753293.5T patent/ES2549860T3/es active Active
- 2007-03-13 US US11/724,029 patent/US8652789B2/en active Active
- 2007-03-13 BR BRPI0708900-7A patent/BRPI0708900A2/pt not_active Application Discontinuation
- 2007-03-13 CA CA2645302A patent/CA2645302C/en active Active
- 2007-03-13 MX MX2008011665A patent/MX2008011665A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009529884A (ja) | 2009-08-27 |
| AU2007225054A1 (en) | 2007-09-20 |
| CA2645302A1 (en) | 2007-09-20 |
| US8652789B2 (en) | 2014-02-18 |
| EP1994415B9 (en) | 2015-12-16 |
| KR101376471B1 (ko) | 2014-03-27 |
| CA2645302C (en) | 2017-07-11 |
| JP5410955B2 (ja) | 2014-02-05 |
| CN101460851B (zh) | 2016-09-21 |
| EP1994415B1 (en) | 2015-07-29 |
| WO2007106595A1 (en) | 2007-09-20 |
| AU2007225054B2 (en) | 2012-08-16 |
| MX2008011665A (es) | 2008-10-08 |
| KR20090008218A (ko) | 2009-01-21 |
| EP1994415A1 (en) | 2008-11-26 |
| US20070264671A1 (en) | 2007-11-15 |
| CN101460851A (zh) | 2009-06-17 |
| BRPI0708900A2 (pt) | 2011-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2549860T3 (es) | Diagnóstico y pronóstico de estados patológicos relacionados con la dipepitidil peptidasa | |
| JP5330381B2 (ja) | 酸化還元電位（ｏｒｐ）を測定及び使用する方法 | |
| ES2702123T3 (es) | Biomarcadores relacionados con la función renal y métodos para utilizarlos | |
| JP5420396B2 (ja) | 粘膜乾燥状態に関する検討 | |
| US8927221B2 (en) | Diagnostic marker for kidney diseases and use thereof | |
| JP6884346B2 (ja) | 糖尿病を判定するための血液試料の分析方法及びシステム | |
| US20160003786A1 (en) | Methods Of Detecting Cancer | |
| MA Aziz | Correlation of urine biomarkers: microalbuminuria and spot urine protein among diabetic patients. application of spot urine protein in diabetic kidney disease, nephropathy, proteinuria estimation, diagnosing and monitoring | |
| Ruggiero et al. | A preliminary study on serum proteomics in fibromyalgia syndrome | |
| TWI532994B (zh) | 用於乳癌篩選的生物標記 | |
| JP2005512059A (ja) | Ｓ１００ｂの測定による敗血症の診断方法 | |
| Isabel Padrão et al. | Proteome‐base biomarkers in diabetes mellitus: Progress on biofluids' protein profiling using mass spectrometry | |
| WO2007003670A1 (es) | Marcadores de fibrosis | |
| JP2018124239A (ja) | 口腔の健康状態の評価方法 | |
| Dawood et al. | Assessment of salivary and serum proteins in patients with oral tumors | |
| JP2015159942A (ja) | 疲労の評価方法 | |
| Kang et al. | Changes of pepsin concentration in saliva sample according to storage period | |
| TWI735470B (zh) | 糖尿病性腎病之判定方法、及於此種判定方法中生物標記之用途 | |
| US20230417774A1 (en) | Method for detecting mild cognitive impairment and mild alzheimer's disease | |
| Chen et al. | The value of biliary amylase and hepatocarcinoma–intestine–pancreas/pancreatitis-associated protein I (HIP/PAP-I) in diagnosing biliary malignancies | |
| JP2009204465A (ja) | 銀染色を用いる電気泳動法により腎疾患等の病態を判定する方法 | |
| US20130084587A1 (en) | Levels of cytokeratins in blood and body fluids as biomarkers for cancer screening, diagnosis and treatment monitoring | |
| US20110008799A1 (en) | Phenotypic ratio of serum amyloid in pre- and type 2 diabetes | |
| Gohel et al. | B-253 Using biomarkers in recurrent renal stone formers to detect silent stones | |
| JP2006300689A (ja) | 肝疾患病態判定用マーカー及び該マーカーを用いる肝疾患病態判定方法 |